Figure 3
From: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
(a) Kaplan–Meier survival curves for the two risk groups of the validation cohort predicted by three-gene predictor. Patients at a high risk (predictive index percentile ⩾67%; n=10) had significantly shorter median survival than patients at a low risk (n=17) (7.4 vs 16.8 months; log rank P=0.047). Green and blue lines represent overall survival curves for the predicted high- and low-risk groups, respectively. (b) Kaplan–Meier survival curves for the two risk groups of the published microarray data set from 40 metastatic gastric cancer patients treated with either fluorouracil-based regimens or cisplatin/irinotecan combination chemotherapy regimen. Patients at a high risk (predictive index percentile ⩾67%; n=6) had shorter median survival than patients at a low risk (n=34), at a borderline significance (3.1 vs 10.8 months; log rank P=0.056). Green and blue lines represent overall survival curves for the predicted high- and low-risk groups, respectively. The color reproduction of the figure is available on the html full text version of the manuscript.
